Signal transduction pathway inhib 
Welcome,         Profile    Billing    Logout  
 10 Companies  6 Products   6 Products   204 Diseases   9 Trials   1461 News 
15 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
perifosine (D21266) / AEterna Zentaris
NCT02238496: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Completed
1
10
US
Cytoreductive surgery, Resection, Perifosine, AEZS-104/D-21266, KRX-0401, Temsirolimus, Torisel
Andrew B Lassman, MD, Pfizer, AEterna Zentaris
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
10/17
02/21
Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
DEFACOVID, NCT04348383 / 2020-001409-21: Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.

Completed
2b
156
Europe
Defibrotide, Placebo
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
COVID19
02/23
02/23
NCT04313036: 5-day Defibrotide Treatment for Hepatic SOS/VOD

Recruiting
2
24
US
Defibrotide
Loyola University
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Bone Marrow Transplant Complications
05/22
08/22
NCT03805581: Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

Completed
2
20
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University
Sickle Cell Disease, Acute Chest Syndrome
07/22
11/23
NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease

Active, not recruiting
2
2
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University, Columbia University, New York University
Kawasaki Disease
10/23
06/24
DF in COVID19, NCT04652115: Defibrotide for the Treatment of Severe COVID-19

Recruiting
2
42
US
Defibrotide
Brigham and Women's Hospital, Jazz Pharmaceuticals
Covid19
09/24
03/25
NCT06182410: Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma

Withdrawn
2
15
NA
Defibrotide, Noravid
University of California, San Francisco, Jazz Pharmaceuticals
Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma, High-risk Neuroblastoma, Thrombotic Microangiopathies
05/27
05/27
NYMC-571, NCT02675959: Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Recruiting
2
40
US
Defibrotide
New York Medical College, University of California, Los Angeles, Medical College of Wisconsin, Tufts Medical Center, Baylor College of Medicine, Johns Hopkins University, Dana-Farber Cancer Institute, Children's Hospital Los Angeles
Sickle Cell Disease
12/24
12/25
NCT05987124: Defibrotide Dose-escalation for SOS Post-HSCT

Recruiting
2
20
US
Defibrotide, Defitelio
New York Medical College
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
08/26
08/27
NCT00263978: Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver

No Longer Available
N/A
US
Defibrotide
Emory University
Liver Diseases
06/09
06/09
NCT00143546: Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver

No Longer Available
N/A
US
Defibrotide, Veno-occlusive disease, VOD, Hepatic veno-occlusive disease.
St. Jude Children's Research Hospital
Hepatic Veno-occlusive Disease
 
 
OPB-111077 / Otsuka
NCT04049825: A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Active, not recruiting
1
36
Japan
OPB-111077
Otsuka Pharmaceutical Co., Ltd.
Relapsed or Refractory Diffuse Large B-cell Lymphoma
03/25
03/25
NCT03063944: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Completed
1
37
US
STAT Inhibitor OPB-111077, OPB-111077, Decitabine, 2'-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 2353-33-5, 5-Aza-2'-deoxycytidine, 5-Aza-2'deoxycytidine, 5-Aza-2-deoxycytidine, 5-Azadeoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Venetoclax, 1257044-40-8, 4-(4-((2-(4-Chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Otsuka America Pharmaceutical
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
01/24
03/24
acetylcysteine zidrimer (OP-101) / Ashvattha Therap
PRANA, NCT04458298: A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

Terminated
2
28
US
OP-101, Placebo
Ashvattha Therapeutics, Inc.
COVID-19
08/22
08/22
homoharringtonine derivative (BS-HH-002.SA) / Bensheng Pharma
NCT04743115: A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS

Not yet recruiting
1
66
NA
BS HH 002.SA
Shanghai Bensen Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
02/25
02/25
YR-006 / Hangzhou Yirui Pharma
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
perifosine (D21266) / AEterna Zentaris
NCT02238496: Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Completed
1
10
US
Cytoreductive surgery, Resection, Perifosine, AEZS-104/D-21266, KRX-0401, Temsirolimus, Torisel
Andrew B Lassman, MD, Pfizer, AEterna Zentaris
Brain Tumor, Recurrent, Glioblastoma, Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Mixed Glioma
10/17
02/21
Defitelio (defibrotide) / IRCCS San Raffaele Hospital, Jazz
DEFACOVID, NCT04348383 / 2020-001409-21: Defibrotide as Prevention and Treatment of Respiratory Distress and Cytokine Release Syndrome of Covid 19.

Completed
2b
156
Europe
Defibrotide, Placebo
Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
COVID19
02/23
02/23
NCT04313036: 5-day Defibrotide Treatment for Hepatic SOS/VOD

Recruiting
2
24
US
Defibrotide
Loyola University
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease, Bone Marrow Transplant Complications
05/22
08/22
NCT03805581: Defibrotide in Sickle Cell Disease-Related Acute Chest Syndrome

Completed
2
20
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University
Sickle Cell Disease, Acute Chest Syndrome
07/22
11/23
NCT04777422: Defibrotide in Children With High Risk Kawasaki Disease

Active, not recruiting
2
2
US
Defibrotide, Defitelio®
New York Medical College, Johns Hopkins University, Columbia University, New York University
Kawasaki Disease
10/23
06/24
DF in COVID19, NCT04652115: Defibrotide for the Treatment of Severe COVID-19

Recruiting
2
42
US
Defibrotide
Brigham and Women's Hospital, Jazz Pharmaceuticals
Covid19
09/24
03/25
NCT06182410: Defibrotide Prophylaxis of Transplant Associated-Thrombotic Microangiopathy for Neuroblastoma

Withdrawn
2
15
NA
Defibrotide, Noravid
University of California, San Francisco, Jazz Pharmaceuticals
Transplant-Associated Thrombotic Microangiopathy, Neuroblastoma, High-risk Neuroblastoma, Thrombotic Microangiopathies
05/27
05/27
NYMC-571, NCT02675959: Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease

Recruiting
2
40
US
Defibrotide
New York Medical College, University of California, Los Angeles, Medical College of Wisconsin, Tufts Medical Center, Baylor College of Medicine, Johns Hopkins University, Dana-Farber Cancer Institute, Children's Hospital Los Angeles
Sickle Cell Disease
12/24
12/25
NCT05987124: Defibrotide Dose-escalation for SOS Post-HSCT

Recruiting
2
20
US
Defibrotide, Defitelio
New York Medical College
Sinusoidal Obstruction Syndrome, Veno-occlusive Disease
08/26
08/27
NCT00263978: Defibrotide Compassionate Use for Patients With Life Threatening Veno-Occlusive Disease of the Liver

No Longer Available
N/A
US
Defibrotide
Emory University
Liver Diseases
06/09
06/09
NCT00143546: Compassionate Use of Defibrotide for Patients With Veno-occlusive Disease of the Liver

No Longer Available
N/A
US
Defibrotide, Veno-occlusive disease, VOD, Hepatic veno-occlusive disease.
St. Jude Children's Research Hospital
Hepatic Veno-occlusive Disease
 
 
OPB-111077 / Otsuka
NCT04049825: A Phase 1 Trial of OPB-111077 in Combination With Bendamustine and Rituximab in Patients With r/r DLBCL

Active, not recruiting
1
36
Japan
OPB-111077
Otsuka Pharmaceutical Co., Ltd.
Relapsed or Refractory Diffuse Large B-cell Lymphoma
03/25
03/25
NCT03063944: STAT Inhibitor OPB-111077, Decitabine and Venetoclax in Treating Patients With Acute Myeloid Leukemia That Is Refractory, Relapsed or Newly Diagnosed and Ineligible for Intensive Chemotherapy

Completed
1
37
US
STAT Inhibitor OPB-111077, OPB-111077, Decitabine, 2'-Deoxy-5-azacytidine, 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one, 2353-33-5, 5-Aza-2'-deoxycytidine, 5-Aza-2'deoxycytidine, 5-Aza-2-deoxycytidine, 5-Azadeoxycytidine, Dacogen, Decitabine for Injection, Deoxyazacytidine, Dezocitidine, Venetoclax, 1257044-40-8, 4-(4-((2-(4-Chlorophenyl)-4, 4-dimethylcyclohex-1-en-1-yl)methyl)piperazin-1-yl)-N-((3-nitro-4-((tetrahydro-2H-pyran-4-ylmethyl)amino)phenyl)sulfonyl)-2-(1H-pyrrolo(2,3-b)pyridin-5-yloxy)benzamide, ABT-0199, ABT-199, ABT199, GDC-0199, RG7601, Venclexta, Venclyxto, Laboratory Biomarker Analysis
Sidney Kimmel Cancer Center at Thomas Jefferson University, Otsuka America Pharmaceutical
Acute Myeloid Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
01/24
03/24
acetylcysteine zidrimer (OP-101) / Ashvattha Therap
PRANA, NCT04458298: A Study to Evaluate OP-101 (Dendrimer N-acetyl-cysteine) in Severe Coronavirus Disease 2019 (COVID-19) Patients

Terminated
2
28
US
OP-101, Placebo
Ashvattha Therapeutics, Inc.
COVID-19
08/22
08/22
homoharringtonine derivative (BS-HH-002.SA) / Bensheng Pharma
NCT04743115: A Phase I, Open-Label, Dose Escalation and Cohort Expansion Study of BS HH 002.SA in Patients With AML and MDS

Not yet recruiting
1
66
NA
BS HH 002.SA
Shanghai Bensen Pharmaceutical Co., Ltd.
Acute Myeloid Leukemia, Myelodysplastic Syndrome
02/25
02/25
YR-006 / Hangzhou Yirui Pharma
No trials found

Download Options